Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) dropped 2.7% on Wednesday after UBS Group lowered their price target on the stock from $28.00 to $24.00. UBS Group currently has a neutral rating on the stock. Pfizer traded as low as $20.92 and last traded at $21.24. Approximately 28,424,445 shares were traded during trading, a decline of 29% from the average daily volume of 39,806,359 shares. The stock had previously closed at $21.84.
Other research analysts also recently issued research reports about the company. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.
Get Our Latest Analysis on PFE
Insider Activity
In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.
Institutional Trading of Pfizer
Institutional investors have recently made changes to their positions in the stock. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Price Performance
The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company's 50 day moving average price is $25.25 and its 200-day moving average price is $26.40. The company has a market cap of $124.14 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
